People | October 04, 2022
Matt Sause elevated as new CEO of Roche Diagnostics
Sause will become CEO Roche Diagnostics and a member of the Corporate Executive Committee effective 1 January 2023.
Sause will become CEO Roche Diagnostics and a member of the Corporate Executive Committee effective 1 January 2023.
The FDA nod marks a step forward in precision oncology, linking molecular diagnostics more tightly to therapy selection for advanced prostate cancer
The test is designed to help clinicians either rule in or rule out amyloid pathology in patients showing signs of cognitive decline
The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities
The new test offers a minimally invasive blood-based approach to tracking neurological damage, measuring neurofilament light chain
The new assay consolidates screening for four major viral threats into a single workflow
The cobas Mass Spec solution Ionify reagent portfolio now covers therapeutic drug monitoring for immunosuppressants and antibiotics
Roche says its new assay “resolves this challenge by delivering accurate and specific results
The PCR-based test, delivered via Roche’s cobas liat system, allows results to be obtained during a patient consultation in GP practices and Emergency Rooms
Test delivers results in just 18 minutes, enabling faster laboratory workflows and patient management during outbreaks
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
